fr 66973 profile

FR 66973: antitumor antibiotic from Streptomyces sandaensis; more potent against B16 melanoma & P388 leukemia than mitomycin C; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	133974
MeSH ID	M0155230

Synonym
fr66973
113202-60-1
fk-973
fr-66973
fk 973
fk973
fr 66973
3,9-epoxy-3h-azirino(2,3-c)(1)benzazocine-5-carboxaldehyde, 1-acetyl-7,9-bis(acetyloxy)-8-(((aminocarbonyl)oxy)methyl)-1,1a,2,8,9,9a-hexahydro-
ccris 6861
11-acetyl-4-formyl-8-carbamoyloxymethyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-6,9-diyl diacetate
11-acetyl-8-carbamoyloxymethyl-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12 ]tetradeca-2,4,6-trien-6,9-diyl diacetate
14-oxa-1,11-diazatetracyclo[7.4.1.0(2,7).0(10,12)]tetradeca-2,4,6-triene, 11-acetyl-6,9-bis(acetyloxy)-4-formyl-8-[(aminocarbonyloxy)methyl]-
1-acetyl-5-formyl-8-{[hydroxy(imino)methoxy]methyl}-1,1a,2,9a-tetrahydro-3,9-epoxyazireno[2,3-c][1]benzazocine-7,9(8h)-diyl diacetate
DTXSID10921015
[11-acetyl-9-acetyloxy-8-(carbamoyloxymethyl)-4-formyl-14-oxa-1,11-diazatetracyclo[7.4.1.02,7.010,12]tetradeca-2(7),3,5-trien-6-yl] acetate

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	7 (43.75)	18.7374
1990's	7 (43.75)	18.2507
2000's	1 (6.25)	29.6817
2010's	1 (6.25)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (5.56%)	5.53%
Reviews	1 (5.56%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	16 (88.89%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
glycine [no description available]	2.01	1	alpha-amino acid; amino acid zwitterion; proteinogenic amino acid; serine family amino acid	EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor; fundamental metabolite; hepatoprotective agent; micronutrient; neurotransmitter; NMDA receptor agonist; nutraceutical
iproniazid [no description available]	1.97	1	carbohydrazide; pyridines
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	2.67	3	mitomycin	alkylating agent; antineoplastic agent
bromodeoxyuridine Bromodeoxyuridine: A nucleoside that substitutes for thymidine in DNA and thus acts as an antimetabolite. It causes breaks in chromosomes and has been proposed as an antiviral and antineoplastic agent. It has been given orphan drug status for use in the treatment of primary brain tumors.	1.97	1	pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent
cytarabine [no description available]	1.97	1	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
benzylamine aminotoluene : Any member of the class of toluenes carrying one or more amino groups.	1.97	1	aralkylamine; primary amine	allergen; EC 3.5.5.1 (nitrilase) inhibitor; plant metabolite
thiazoles [no description available]	1.97	1	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
tranylcypromine Tranylcypromine: A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders. (From AMA Drug Evaluations Annual, 1994, p311). tranylcypromine : A racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).. (1R,2S)-tranylcypromine : A 2-phenylcyclopropan-1-amine that is the (1R,2S)-enantiomer of tranylcypromine.	1.97	1	2-phenylcyclopropan-1-amine
nimustine Nimustine: Antineoplastic agent especially effective against malignant brain tumors. The resistance which brain tumor cells acquire to the initial effectiveness of this drug can be partially overcome by the simultaneous use of membrane-modifying agents such as reserpine, calcium antagonists such as nicardipine or verapamil, or the calmodulin inhibitor, trifluoperazine. The drug has also been used in combination with other antineoplastic agents or with radiotherapy for the treatment of various neoplasms.. nimustine : An organochlorine compound that is urea in which the two hydrogens on one of the amino groups are replaced by nitroso and 2-chloroethyl groups and one hydrogen from the other amino group is replaced by a 4-amino-2-methylpyrimidin-5-ylmethyl] group. An antineoplastic agent especially effective against malignant brain tumors.	1.97	1	aminopyrimidine; N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	1.97	1	organic bromide salt	colorimetric reagent; dye
methotrexate [no description available]	1.97	1	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
fr 900482 FR 900482: isolated from Streptomyces sandaensis; structure given in above source	3.55	2
vinylglycine vinylglycine: irreversible inhibitor of aspartate aminotransferase; structure. L-vinylglycine : A non-proteinogenic L-alpha-amino acid with a structure in which a vinyl group is bonded to the alpha-carbon of glycine.	2.01	1	glycine derivative; L-alpha-amino acid zwitterion; non-proteinogenic L-alpha-amino acid	EC 4.4.1.14 (1-aminocyclopropane-1-carboxylate synthase) inhibitor
amrubicin amrubicin: structure in first source; a 9-amino-anthracycline antibiotic. amrubicin : A synthetic anthracycline antibiotic with molecular formula C25H25NO9. A specific inhibitor of topoisomerase II, it is used (particularly as the hydrochloride salt) in the treatment of cancer, especially lung cancer, where it is a prodrug for the active metabolite, ambrucinol.	1.97	1	anthracycline antibiotic; methyl ketone; primary amino compound; quinone; tetracenes	antineoplastic agent; prodrug; topoisomerase II inhibitor
didimethylsulfoxide dichloroplatinum(ii) [no description available]	1.97	1
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	3.19	1	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
piperidines Piperidines: A family of hexahydropyridines.	3.19	1
11-acetyl-8-carbamoyloxymethyl,4-formyl-6-methoxy-14-oxa-1,11-diazatetracyclo(7.4.1.0.0)tetradeca-2,4,6-trien-9-yl acetate FK 317 dihydrobenzoxazine: a substituted dihyrobenzoxazine; structure given in first source	1.99	1

Condition	Relationship Strength	Studies	Trials
Disease Exacerbation [description not available]	3.01	1	0
Benign Neoplasms [description not available]	3.01	1	0
Invasiveness, Neoplasm [description not available]	3.01	1	0
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	3.01	1	0
Abnormalities, Autosome [description not available]	1.98	1	0
Capillary Leak Syndrome A condition characterized by recurring episodes of fluid leaking from capillaries into extra-vascular compartments causing hematocrit to rise precipitously. If not treated, generalized vascular leak can lead to generalized EDEMA; SHOCK; cardiovascular collapse; and MULTIPLE ORGAN FAILURE.	1.99	1	0
Experimental Neoplasms [description not available]	2.67	3	0
Pleural Effusion Presence of fluid in the pleural cavity resulting from excessive transudation or exudation from the pleural surfaces. It is a sign of disease and not a diagnosis in itself.	1.99	1	0
Adenocarcinoma, Basal Cell [description not available]	1.97	1	0
Breast Cancer [description not available]	1.97	1	0
Atypical Ductal Hyperplasia [description not available]	1.97	1	0
Carcinoma, Epidermoid [description not available]	1.97	1	0
Cancer of Mouth [description not available]	1.97	1	0
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.97	1	0
Breast Neoplasms Tumors or cancer of the human BREAST.	1.97	1	0
Carcinoma, Intraductal, Noninfiltrating A noninvasive (noninfiltrating) carcinoma of the breast characterized by a proliferation of malignant epithelial cells confined to the mammary ducts or lobules, without light-microscopy evidence of invasion through the basement membrane into the surrounding stroma.	1.97	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.97	1	0
Mouth Neoplasms Tumors or cancer of the MOUTH.	1.97	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	2.66	3	0
Cancer of Lung [description not available]	2.66	3	0
B16 Melanoma [description not available]	1.97	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	2.66	3	0
Symptom Cluster [description not available]	3.36	1	1
Syndrome A characteristic symptom complex.	3.36	1	1
Vascular Diseases Pathological processes involving any of the BLOOD VESSELS in the cardiac or peripheral circulation. They include diseases of ARTERIES; VEINS; and rest of the vasculature system in the body.	3.36	1	1
Benign Neoplasms, Brain [description not available]	2.38	2	0
Glial Cell Tumors [description not available]	2.38	2	0
Brain Neoplasms Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.	2.38	2	0
Glioma Benign and malignant central nervous system neoplasms derived from glial cells (i.e., astrocytes, oligodendrocytes, and ependymocytes). Astrocytes may give rise to astrocytomas (ASTROCYTOMA) or glioblastoma multiforme (see GLIOBLASTOMA). Oligodendrocytes give rise to oligodendrogliomas (OLIGODENDROGLIOMA) and ependymocytes may undergo transformation to become EPENDYMOMA; CHOROID PLEXUS NEOPLASMS; or colloid cysts of the third ventricle. (From Escourolle et al., Manual of Basic Neuropathology, 2nd ed, p21)	2.38	2	0
Leukemia L 1210 [description not available]	2.66	3	0
Carcinoma, Oat Cell [description not available]	1.97	1	0
Carcinoma, Non-Small Cell Lung [description not available]	2.37	2	0
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	2.37	2	0
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	1.97	1	0

fr 66973

Description

Cross-References

Synonyms (15)

Research

Studies (16)

Market Indicators

Research Demand Index: 11.36

Study Types